Spending smarter, not just spending more, is how India saves lives
India's Ayushman Bharat scheme has extended a meaningful hand to millions of cancer patients since 2018, accelerating treatment access and softening the financial devastation that diagnosis so often brings to vulnerable households. Yet a new study by oncologists and health economists lays bare a quiet crisis within the program's success: the annual funding gap between what exists and what comprehensive cancer care demands stands at Rs 25,300 crore. The program has opened a door that was once sealed shut, but the room beyond remains only partially furnished. The question before India now is whether the political will exists to move from a breakthrough that saves some to a system that saves all it could.
- 68 lakh cancer patients have received care under Ayushman Bharat, yet the scheme's Rs 7,700 crore annual allocation covers less than a quarter of the Rs 33,000 crore needed for full five-year treatment.
- Patients can now reach hospitals faster — treatment initiation improved by 90% post-diagnosis — but annual benefit caps of Rs 5 lakh leave many exhausted mid-treatment, stranded at the edge of recovery.
- The FinCan study warns that the absence of diagnostic coverage, representing just 3% of total cancer costs, is quietly pushing patients toward late-stage diagnoses that are far more expensive and far less survivable.
- Researchers propose a revolving five-year ceiling of Rs 25 lakh with Rs 10 lakh top-ups for advanced cases, a structural redesign that could prevent the artificial cliff where coverage ends and catastrophe begins.
- Early detection integration into existing health centers could save Rs 5,000 crore annually and more than 30,000 lives per year — making prevention not a moral aspiration but the most economically rational intervention available.
- The government has begun responding with 200 new day care cancer centers and reduced drug duties, but whether the deeper structural reforms will follow remains the defining question for millions of patients.
India's Ayushman Bharat scheme has become a genuine lifeline for cancer patients who would otherwise face financial ruin. Since 2018, the program has covered more than 68 lakh cancer cases worth roughly Rs 13,000 crore, fundamentally shifting access to care for rural and low-income populations. Yet a new study reveals a stark paradox: the program works, but not nearly well enough. The gap between current funding and what comprehensive cancer care actually costs amounts to Rs 25,300 crore annually — a shortfall large enough to threaten the full arc of modern treatment.
The FinCan study, led by Dr. Abhishek Shankar at AIIMS Delhi and conducted by oncologists and health economists, documents both real achievements and structural limitations. Enrollment in Ayushman Bharat raised the likelihood of starting treatment within 30 days of diagnosis by roughly 90 percent. Targeted therapies now reach patients who previously had no access. But delivering the full five-year standard of care — diagnostics, surgery, medications, radiotherapy, and follow-up — requires approximately Rs 33,000 crore annually. The program currently allocates Rs 7,700 crore. Patients can reach treatment; the system cannot yet afford to complete it.
Dr. Shankar framed the challenge as one of strategic spending rather than simply spending more. Faster diagnosis and treatment initiation could save Rs 1,500 crore annually while producing 1,560 additional survivors per year. Embedding early detection aligned with international standards could save Rs 5,000 crore annually and over 30,000 additional lives. The paradox is precise: underinvesting in prevention costs far more in the long run.
The study proposes replacing the current Rs 5 lakh annual family cap with a five-year revolving ceiling of Rs 25 lakh, allowing patients to draw more heavily in expensive early years without hitting an artificial cliff mid-treatment. A Rs 10 lakh top-up for advanced-stage cancers — which account for 30 to 37 percent of cases — is also recommended. Critically, diagnostics, which represent only 3 percent of total cancer costs but frequently fall outside the scheme entirely, should be embedded into existing health centers to prevent the delays that push patients toward late-stage diagnosis.
India's government has already moved in this direction, allocating funds for 200 new day care cancer centers and reducing customs duties on several cancer medications. These steps signal recognition of both the program's promise and its limits. Whether the deeper structural reforms the FinCan study recommends will follow at scale remains the question on which millions of lives quietly depend.
India's Ayushman Bharat scheme has become a genuine lifeline for cancer patients who would otherwise face financial ruin seeking treatment. Since its launch in 2018, the program has covered more than 68 lakh cancer cases worth roughly 13,000 crore rupees, fundamentally shifting access to care for rural and low-income populations. Yet a new study reveals a stark paradox: the program works, but it doesn't work nearly well enough. The gap between what the scheme currently funds and what comprehensive cancer care actually costs amounts to 25,300 crore rupees annually—a shortfall so large it threatens to limit the program's ability to deliver the full arc of modern treatment.
The FinCan study, led by Dr. Abhishek Shankar at AIIMS Delhi's cancer institute and conducted by oncologists and health economists, examined both the program's genuine achievements and its structural limitations. The evidence of success is real. A study published in The Lancet found that enrollment in Ayushman Bharat raised the likelihood of starting cancer treatment within 30 days of diagnosis by roughly 90 percent compared to pre-2018 patterns. Targeted therapies—the sophisticated drugs that represent modern oncology—now reach patients who previously had no access to them. The scheme has demonstrably accelerated treatment initiation and reduced the catastrophic financial burden that cancer diagnosis typically imposes on Indian households.
But here is where the numbers become sobering. Delivering the full five-year standard of care for cancer—diagnostics, surgery, targeted medications, radiotherapy, and follow-up monitoring—would require approximately 33,000 crore rupees annually. The Ayushman Bharat program currently allocates only 7,700 crore rupees per year for cancer care. That leaves a gap of 25,300 crore rupees. The program has solved the access problem in many ways, but it has not solved the adequacy problem. Patients can now reach treatment, but the system cannot yet afford to give them the complete treatment they need.
Dr. Shankar framed the challenge not as a simple matter of spending more, but of spending more strategically. The FinCan models suggest that if the system accelerated diagnosis and treatment initiation—getting patients into care faster—it would save approximately 1,500 crore rupees annually while producing 1,560 additional survivors per year. More dramatically, if India implemented early detection and screening aligned with international standards, the annual savings would reach 5,000 crore rupees, with over 30,000 additional lives saved each year. The paradox is that spending less on prevention and early detection costs far more in the long run.
The study proposes concrete structural reforms. The current system caps coverage at 5 lakh rupees per family per year. The researchers recommend replacing this with a five-year "revolving ceiling" of 25 lakh rupees, allowing patients to draw more heavily in expensive years—typically the first year of treatment—and less in later years. This would prevent the artificial cliff where patients exhaust their annual benefit mid-treatment. Additionally, the study recommends a 10 lakh rupee top-up specifically for advanced-stage cancers, which account for 30 to 37 percent of cases and require particularly expensive interventions.
A critical gap the study identifies is diagnostic coverage. Diagnostics represent only 3 percent of total cancer care costs, yet they often fall outside the Ayushman Bharat package entirely, creating delays that push patients toward late-stage diagnosis. The researchers recommend embedding screening and diagnostic services into the scheme through existing health centers, a change that could simultaneously save lives and reduce overall costs. Early detection, they argue, is not a luxury—it is the most cost-effective intervention available.
India's government has already begun moving in this direction. The 2025-26 Union Budget allocated funds to establish 200 new day care cancer centers in district hospitals, expanding access beyond tertiary institutions. Customs duties on several cancer medications were also reduced or eliminated, lowering drug costs directly. These steps suggest policymakers recognize both the program's success and its limitations. The question now is whether the structural reforms the FinCan study recommends—the revolving ceiling, the diagnostic integration, the top-up for advanced cases—will be implemented at scale. If they are, the study projects that India could save thousands of lives annually while reducing the economic burden of cancer on families. If they are not, the Ayushman Bharat scheme will remain what it is now: a genuine breakthrough that still falls short of what cancer patients actually need.
Notable Quotes
Better cancer care is not only about spending more but also about spending smarter, especially where early diagnosis and well-designed coverage can prevent both late-stage suffering and catastrophic costs.— Dr. Abhishek Shankar, lead researcher, FinCan study
The Hearth Conversation Another angle on the story
The study says the scheme has helped 68 lakh cancer patients, but there's still a 25,300 crore rupee gap. How is that possible if the program is working?
It's working in the sense that it's getting people into treatment who would never have afforded it before. But "working" and "complete" are different things. The scheme covers some treatments well, but full cancer care—diagnostics, surgery, drugs, radiation, follow-up—costs 33,000 crore annually. They're only funding 7,700 crore. So patients get access, but not always the full course of care they need.
Why is diagnostics such a problem if it's only 3 percent of costs?
Because those small costs happen first. If diagnostics aren't covered, patients delay getting tested. By the time they do, the cancer is advanced and far more expensive to treat. It's a false economy—saving money on diagnostics costs you money on treatment.
The study mentions a "revolving ceiling" instead of the current annual cap. What changes for a patient?
Right now, a family gets 5 lakh rupees per year. If treatment costs 8 lakh in year one, they're stuck. With a revolving five-year ceiling of 25 lakh, they can use more in expensive years and less later. It's designed around how cancer actually unfolds, not around arbitrary annual boundaries.
And the 10 lakh top-up for advanced cases—who decides who gets that?
The study suggests it targets the 30 to 37 percent of patients with high-stage cancers that require particularly expensive treatments. It's not universal, but it's targeted at the cases that would otherwise bankrupt families or go untreated.
If early detection could save 5,000 crore rupees annually and 30,000 lives, why hasn't that been the priority?
Because prevention is invisible. You don't see the lives saved or the money not spent. You see the people in treatment centers. Policymakers tend to fund what's visible and urgent, not what's preventive and quiet. But the math is clear: early detection is the most cost-effective intervention available.